PainReform Ltd. (NASDAQ:PRFX) Short Interest Down 76.0% in November

PainReform Ltd. (NASDAQ:PRFX) saw a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 29,100 shares, a decrease of 76.0% from the October 31st total of 121,100 shares. Currently, 5.2% of the company’s shares are short sold. Based on an average daily trading volume, of 904,100 shares, the short-interest ratio is presently 0.0 days.

PainReform Stock Performance

PRFX stock traded up $0.03 during midday trading on Wednesday, reaching $2.75. The company’s stock had a trading volume of 178,981 shares, compared to its average volume of 268,438. PainReform has a 1 year low of $1.73 and a 1 year high of $80.64. The firm has a market capitalization of $398,750.00, a price-to-earnings ratio of -0.02 and a beta of 0.56. The stock has a fifty day simple moving average of $2.61 and a two-hundred day simple moving average of $2.28.

Analysts Set New Price Targets

Separately, Maxim Group restated a “hold” rating on shares of PainReform in a research report on Thursday, October 24th.

Institutional Investors Weigh In On PainReform

A hedge fund recently raised its stake in PainReform stock. Armistice Capital LLC lifted its stake in shares of PainReform Ltd. (NASDAQ:PRFX) by 76.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 276,000 shares of the company’s stock after acquiring an additional 120,000 shares during the quarter. Armistice Capital LLC owned approximately 13.60% of PainReform worth $132,000 at the end of the most recent reporting period. 37.28% of the stock is owned by institutional investors and hedge funds.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.